ATNM
AMEXActinium Pharmaceuticals Inc. (Delaware)
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.04-0.02 (-1.88%)
02:00 PM07:45 PM
News · 26 weeks16+75%
2025-12-142026-06-07
Mix1490d
- Other9(64%)
- SEC Filings4(29%)
- Offering1(7%)
Latest news
25 items- PRActinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung CancerNew KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced their effect in combination Additional data in the EGFR-mutant setting demonstrated powerful synergy with osimertinib due to enhanced target expression in treated animals resulting in complete tumor regression in the combination arm The data with EGFR and KRAS mutations which account for approximately 40-50 percent of all NSCLC cases provide compelling evidence of the potential of ATNM-400 as a monotherapy or in combination with inhibitory agents against these mutations ATNM
- PRActinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer ModelsNew data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi®), apalutamide (Erleada®), and darolutamide (Nubeqa®)- directly targeting the point of failure for a high proportion of mCRPC patients ATNM-400 substantially outperformed apalutamide and darolutamide in an ARPI-resistant tumor model, and in combination with either ARPI it showed durable complete responses, supporting both monotherapy and combination strategies in refractory disease similar to prior data with enzalutamide ATNM-400 delivered superior tumor control as a single bolus or repeat dose with a consistent
- PRActinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline DevelopmentProven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumorsPlayed a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster statusLed clinical development as CMO of NBE Therapeutics which was acquired by Boehringer Ingelheim for $1.4 billion, and most recently CMO of radiotherapy company Full-Life TechnologiesTimely key hire with Dr. Heeger's operational rigor and clinical expertise expected to elevate development of Actimab-A,
- PRActinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 RadioconjugatesOptimization of chelator-to-antibody ratio (CAR) is a key design parameter for next-generation radioconjugates, presenting tunable levers Actinium is utilizing to engineer more effective drug candidatesOptimized CAR improved tumor targeting, internalization, and pharmacokinetics of 225Ac-labeled antibodiesLower-CAR conjugates preserved tumor targeting while reducing off-target liver and spleen uptake, supporting a wider therapeutic window that may enable higher, safer dosingFindings reinforce Actinium's proprietary radiochemistry expertise and directly support the Company's broader radioconjugate pipeline a capability that applies to every program from the platformNEW YORK, June 1, 2026 /PRN
- PRActinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT ProgramsTogether the allowances deepen protection across two priority franchises and reinforce a patent estate of approximately 250 issued and pending patents and patent applications worldwideNEW YORK, May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Canadian Intellectual Property Office (CIPO) has issued Notices of Allowance for two patent applications spanning the Company's Actimab-A and Iomab-ACT programs. The allowances broaden Actinium's intellectual property protection across both hematologic malignancies and next-generation conditioning for gene-edited cell-based
- PRActinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards NoticeNEW YORK, May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced it will provide a program update on its first-in-class Actinium-225 (225Ac) antibody radioconjugate, ATNM-400, highlighting new data that will be showcased across three presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, taking place May 30-June 2, 2026, in Los Angeles, California. Two of the presentations showcase ATNM-400's differentiated profile across prostate cancer and non-small cell lung cancer (NSCLC), while a third demonstrates the importance of radioconjuga
- SECActinium Pharmaceuticals Inc. (Delaware) filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- SECSEC Form 10-Q filed by Actinium Pharmaceuticals Inc. (Delaware)10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- PRActinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization– ATNM-400 in NSCLC: New data demonstrates ATNM-400's potential in KRAS-mutatedmodels supporting its development as a mutation-agnostic therapy in settings whereresistance to EGFR- and KRAS-targeted agents remains a major clinical challenge– ATNM-400 in prostate cancer: New data further supports ATNM-400 as a potentialtreatment option across the spectrum of PSMA-high, PSMA-low, and PSMA-negativedisease, addressing a key limitation of PSMA-targeted therapies – Radioconjugation platform: New data demonstrates that optimizing chelator-to-antibody ratio(CAR) improves tumor targeting, internalization, and pharmacokinetics of 225Ac-labeledantibodies, directly supporting ATNM-400 development and re
- PRActinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual MeetingATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potentialIn prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settingsIn EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab b
- PRActinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual MeetingActimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies including revumenib (menin-KMT2A inhibitor), gilteritinib (FLT3 inhibitor), and azacitidine (hypomethylating agent) - three pillars of modern AML treatment - supporting its potential role as a universal combination backboneTranscriptional reprogramming identified as a central mechanism showing that Actimab-A combinations don't just add cytotoxicity, they reprogram AML cells from proliferation toward differentiation and apoptosis, providing the mechanistic basis for deeper, more durable MRD-negative
- PRActinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual MeetingNew data underscoring the potential of ATNM-400 as a first-in-class Ac-225 radioconjugate with broad pan-tumor efficacy across multiple solid tumor models Actimab-A demonstrates mutation-agnostic efficacy and a novel mechanism that enhances response to standard AML therapies Multiple data catalysts for ATNM-400 and Actimab-A in 2026; and posters for each to be presented on April 21, 2026 at AACR 2026 in San Diego, CANEW YORK, April 6, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the publication of two abstracts that will be presented at the American Association for Cancer Re
- SECSEC Form 10-K filed by Actinium Pharmaceuticals Inc. (Delaware)10-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- SECAmendment: Actinium Pharmaceuticals Inc. (Delaware) filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K/A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- PRActinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual MeetingAACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology ApplicationsNEW YORK, Feb. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted radiotherapies, today announced that it will present two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California. Both abstracts are scheduled for presentation in the Experimental and Molecular Therap
- SECActinium Pharmaceuticals Inc. (Delaware) filed SEC Form 8-K: Leadership Update8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- PRActinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025- ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the HER2 therapy trastuzumab - The Actinium-225 alpha-emitter payload of ATNM-400 induced irreversible double-strand DNA breaks and has the potential to produce potent localized tumor killing with reduced off-target lung toxicity that limits the use of antibody drug conjugates - Data supports the continued development of ATNM-400 as a monotherapy or combination therapy to address multiple breast cancer subtypes with limited treatment options NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Actinium
- PRActinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer SymposiumPresentation to include new data in triple-negative disease, a breast cancer subtype with poor outcomes and limited viable treatment optionsATNM-400 overcomes HER2 therapy resistance and represents a novel targeted radiotherapy with the potential to avoid off-target toxicities including ILD that constrains other therapeutic modalities such as antibody drug conjugatesATNM-400 has demonstrated the potential to overcome resistance to first-line tamoxifen endocrine therapyData to be presented on December 11, 2025 at 5:00 PM CTNEW YORK, Dec. 1, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM), a leader in the development of differentiated targeted radiotherapies, today announced c
- SECActinium Pharmaceuticals Inc. (Delaware) filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- SECSEC Form 10-Q filed by Actinium Pharmaceuticals Inc. (Delaware)10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- SECSEC Form DEF 14A filed by Actinium Pharmaceuticals Inc. (Delaware)DEF 14A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- PRActinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications- New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new treatment options beyond tamoxifen and trastuzumab - ATNM-400 demonstrates efficacy across prostate cancer, non-small cell lung cancer (NSCLC), and breast cancer - three of the largest oncology indications - with potential as monotherapy, in combination, or as an alternative therapy NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that new preclinical data for its lead antibody radioconjuga
- PRActinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat ConferenceNEW YORK, Nov. 3, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that Sandesh Seth, Chairman and CEO will be participating in the Stephens Biotechnology Virtual Fireside Chat. During the conference, members of Actinium's management team will also be available for one-on-one meetings with investors. Date: November 4, 2025Time: 10:30-11:20 am ETFormat: Virtual fireside chat To join the conference meetings or to obtain more information,
- PRActinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics- ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO®), second line therapy Dato-DXd (Trop-2 ADC DATROWAY®) and third line therapy amivantamab (EGFR-cMET bispecific RYBREVANT®) - Combination of ATNM-400 and osimertinib resulted in complete tumor regression in 100% of tumor bearing animals; synergistic mechanism supported by increased ATNM-400 target antigen expression after EGFR inhibition with osimertinib - Improved progression free survival has been demonstrated clinically with the combination of osimertinib and external beam radiotherapy providing strong rationale for a combination with targeted al
- PRActinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat- ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology withcontinued expression following androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy, enabling potent activity independent of PSMA expression - ATNM-400 demonstrated superior efficacy over PSMA-targeted radioligand therapy(177Lu-PSMA-617 and 225Ac-PSMA-617) with enhanced tumor control and prolonged survival in low-PSMA and treatment-resistant models - Demonstrated durable anti-tumor responses, exceeding those achieved with the ARPI enzalutamide - Combination of ATNM-400 with enzalutamide achieved complete tumor regressionin 40% of prostate cancer-bearing animals, demonstrating strong mechan
ATNM FAQ
6 questionsWhat does Actinium Pharmaceuticals Inc. (Delaware) do?
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of...Where does ATNM stock trade?
Actinium Pharmaceuticals Inc. (Delaware) (ATNM) is listed on AMEX.What sector and industry is ATNM in?
Actinium Pharmaceuticals Inc. (Delaware) operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ATNM?
Actinium Pharmaceuticals Inc. (Delaware) has had 7 recent analyst actions on file. The most recent action was from B. Riley Securities: Neutral with a $200.00 price target on 2024-08-07.What companies are similar to ATNM?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ATNM side-by-side with any of them on Quantisnow.How can I track ATNM on Quantisnow?
Quantisnow aggregates Actinium Pharmaceuticals Inc. (Delaware)'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATNM to receive live email and push alerts on every new disclosure.